Acquisition furthers Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma

Dr. Halit Bander named VP, Oncology, Medical Affairs; Moyra Knight named VP, Corporate Communications; Maribeth Landwehr named Executive Director, Corporate Communications

First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC

-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed-

Employees Also Raised More Than $55,000 at Third Annual "One Astellas Spirit Run" for Seven Charitable Organizations

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-

2018 Challenge Will Award a Total of $100,000 in New Grants to Help Reduce the Unequal Burden of Cancer